Ligand Pharmaceuticals Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise noted. Ligand is a biopharmaceutical company that earns royalties, sells Captisol and provides financing and licensing to support drug development. OmniAb is reported as a discontinued operation.
Key financial results
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Total revenue and other income | $31.0 million | $44.0 million |
| Operating income | $3.0 million | $14.2 million |
| Net income | $86.1 million | $41.9 million |
| Diluted EPS | $4.75 | $2.33 |
| Operating cash flow | $18.7 million | $33.9 million |
- Revenue mix: Royalties were $19.1 million, up 8%; Captisol revenue was $9.2 million, down 13%; contract revenue and other income was $2.7 million, down 83%. Lower contract income primarily reflected the absence of the Q1 2023 milestone tied to FDA approval of Travere’s FILSPARI.
- Margins and expenses: Operating expenses fell 6% to $28.0 million, but operating margin declined to about 9.6% from 32.3% as revenue fell. Captisol sales declined primarily due to order timing. R&D expense decreased following the Pelican business sale; G&A was broadly unchanged.
- Investment-related earnings: The $86.1 million net income includes $110.8 million of gains from short-term investments. Ligand reported $60.0 million of realized gains after selling 0.7 million Viking shares and $50.8 million of unrealized gains, principally from Viking and other equity securities. These gains are not recurring operating revenue.
- Liquidity: Cash and cash equivalents were $50.1 million and short-term investments were $260.5 million at March 31, 2024, totaling $310.6 million, up $140.3 million from year-end. Current assets were $368.9 million versus current liabilities of $17.8 million.
- Debt and financing: The filing reports no outstanding revolver borrowings; $74.4 million remained available under the $75 million revolving facility after a $0.6 million letter of credit. The facility matures October 12, 2026. The prior $76.9 million principal balance on convertible notes was repaid at maturity in May 2023. Total liabilities were $107.3 million.
- Cash flows: Operating cash flow was $18.7 million, investing cash flow was a use of $3.8 million, and financing cash flow provided $12.2 million. Cash and cash equivalents increased $27.1 million during the quarter.
Material changes, outlook and risks
- Royalties rose, led by growth in Kyprolis, Rylaze and Vaxneuvance and new FILSPARI royalties; declines in Evomela and teriparatide partly offset those gains. Captisol and contract income decreased.
- Ligand said existing funds, operating cash generation and financing access should be adequate for planned needs. The filing provides no specific full-year revenue or earnings guidance.
- After quarter-end, Ligand announced a $75 million Agenus royalty financing, with an option to invest another $25 million and potential syndication that could bring the aggregate purchase price to $200 million. Closing was expected in May 2024 and remained subject to customary conditions as described in the filing. The agreement includes rights to royalties and milestones from partnered oncology programs and a royalty on Agenus’ BOT/BAL program.
- Ligand created Pelthos Therapeutics to commercialize ZELSUVMI (berdazimer gel), acquired with Novan assets; U.S. commercial availability was expected by late 2024. These commercial and partnered-product expectations depend on execution, regulatory and market outcomes.
- Relevant development risks include partner product sales and approvals, clinical-trial outcomes, Captisol order variability and the valuation of publicly traded investments. Ligand reported a $2.4 million equity-method loss from Primrose Bio and a $3.0 million reduction in the Elutia expected-credit-loss allowance after an agreement amendment. The filing disclosed opioid-related litigation involving several Indian tribes; Ligand said no individualized factual allegations had been made against it and that it intends to defend the claims.
- Management reported effective disclosure controls as of March 31, 2024 and no material changes in internal control over financial reporting during the quarter. It reported no material changes to previously disclosed risk factors.
Important facts for investors to verify
- How much reported earnings and investment value depend on Viking shares, and the effect of subsequent share-price movements or further sales.
- Whether the Agenus financing closed on the expected terms, and the timing, funding and economics of any optional investment or syndication.
- Progress and partner-reported sales for key royalty products, including Kyprolis, Rylaze, FILSPARI and Vaxneuvance, as well as Captisol order trends.
- Regulatory and commercial milestones, including the expected ensifentrine FDA action date of June 26, 2024 and the planned late-2024 U.S. launch of ZELSUVMI.
- Future cash generation, any revolver usage, and the recoverability of financial royalty assets, particularly as underlying products develop or commercialize.